US Drug Recall Register
Class II · Moderate risk Terminated Initiated Mar 11, 2022 (4 years ago)

Sucralfate Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Labeling: Label Mix-Up

What was recalled

Sucralfate Oral Suspension, USP 1g/10mL, packaged in a) 40 case of 10 mL unit Dose Cups (NDC 69339-148-17) and b) 100 case of 10 mL Unit Dose Cups (NDC 69339-148-19) Rx Only, Dash Pharmaceuticals, Upper Saddle River, NJ 07458.

Recalling firm
DASH Pharmaceuticals LLC
NDC code
69339-148-17
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0749-2022

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Sucralfate recalls

See all
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Amerisource Health Services LLC NDC 60687-695-01 D-0027-2026
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Amerisource Health Services LLC NDC 60687-695-01 D-0598-2025
Class II · Moderate risk Ongoing

Sucralfate Tablets

Reason CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess, rendering the products adulterated.

Nostrum Laboratories, Inc. NDC 29033-0003-01 D-0547-2025
Class I · High risk Terminated

Sucralfate Oral Suspension

Reason Microbial Contamination of Non-Sterile Products: identified as Bacillus cereus.

VistaPharm LLC NDC 66689-305-16 D-0047-2024
Class II · Moderate risk Terminated

Sucralfate Oral Suspension 1g per 10mL

Reason Superpotent/Subpotent single ingredient Drug: Out of Specification Assay results

VistaPharm LLC NDC 66689-305-16 D-1149-2023